FDA Finalises Rules for Apps Bundled With Prescription Drugs

The US Food and Drug Administration issued final guidance this morning governing software applications distributed by or on behalf of drug sponsors for use alongside prescription medicines. The document distinguishes between software functions requiring formal device review and promotional or informational tracking tools that simply accompany a therapy. Under the policy, software that actively calculates a dose or alters drug administration faces standard medical device oversight, while basic symptom logs and dose reminders remain subject to standard postmarket drug surveillance.

Drug developers increasingly distribute companion software powered by basic machine learning models to track adherence, log daily side effects, and predict missed doses. In practice, these tools have often functioned as continuous consumer data pipelines under lax regulatory scrutiny, collecting subjective wellness metrics alongside hard clinical data without clear verification that the software improves clinical outcomes.

If you are prescribed a medication that comes paired with an application, inspect the software permissions immediately. Check whether your logged symptoms remain protected under clinical oversight frameworks or are routed to commercial databases as non-regulated user activity.